
Opinion|Videos|November 7, 2024 (Updated: November 7, 2024)
Addressing Unsatisfactory Responses in Chronic MDD
Experts in the management of depression discuss managing unsatisfactory responses in chronic MDD, focusing on anhedonia and its role in disability. They explore strategies to improve treatment outcomes and address the persistent challenges faced by patients with chronic depressive symptoms.
Advertisement
Episodes in this series

Advertisement
Related to this article

Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.

Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.

Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.

How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.

RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk
2
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
3
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
4
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
5

